{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:14:44Z","timestamp":1794107684802,"version":"4.8.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"has served on Advisory Board for DISC Medicine and Agios"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01231-x","type":"journal-article","created":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T08:39:56Z","timestamp":1740818396000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Myeloid neoplasms with PHF6 mutations: context-dependent genomic and prognostic characterization in 176 informative cases"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9979-7923","authenticated-orcid":false,"given":"Saubia","family":"Fathima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Alsugair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6116-8163","authenticated-orcid":false,"given":"Rong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2458-9887","authenticated-orcid":false,"given":"Abhishek A.","family":"Mangaonkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2730-8593","authenticated-orcid":false,"given":"Kebede H.","family":"Begna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Animesh","family":"Pardanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinthya J.","family":"Zepeda Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5439-0778","authenticated-orcid":false,"given":"Kaaren K.","family":"Reichard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-6172","authenticated-orcid":false,"given":"Naseema","family":"Gangat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4605-3821","authenticated-orcid":false,"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,1]]},"reference":[{"key":"1231_CR1","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/ng.542","volume":"42","author":"P Van Vlierberghe","year":"2010","unstructured":"Van Vlierberghe P, Palomero T, Khiabanian H, Van der Meulen J, Castillo M, Van Roy N, et al. PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet. 2010;42:338\u201342.","journal-title":"Nat Genet"},{"key":"1231_CR2","doi-asserted-by":"publisher","first-page":"10069","DOI":"10.1074\/jbc.M113.535351","volume":"289","author":"Z Liu","year":"2014","unstructured":"Liu Z, Li F, Ruan K, Zhang J, Mei Y, Wu J, et al. Structural and functional insights into the human Borjeson-Forssman-Lehmann syndrome-associated protein PHF6. J Biol Chem. 2014;289:10069\u201383.","journal-title":"J Biol Chem"},{"key":"1231_CR3","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/ng1040","volume":"32","author":"KM Lower","year":"2002","unstructured":"Lower KM, Turner G, Kerr BA, Mathews KD, Shaw MA, Gedeon AK, et al. Mutations in PHF6 are associated with Borjeson-Forssman-Lehmann syndrome. Nat Genet. 2002;32:661\u20135.","journal-title":"Nat Genet"},{"key":"1231_CR4","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3390\/genes6020325","volume":"6","author":"MA Todd","year":"2015","unstructured":"Todd MA, Ivanochko D, Picketts DJ. PHF6 degrees of separation: the multifaceted roles of a chromatin adaptor protein. Genes (Basel). 2015;6:325\u201352.","journal-title":"Genes (Basel)"},{"key":"1231_CR5","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/leu.2010.247","volume":"25","author":"P Van Vlierberghe","year":"2011","unstructured":"Van Vlierberghe P, Patel J, Abdel-Wahab O, Lobry C, Hedvat CV, Balbin M, et al. PHF6 mutations in adult acute myeloid leukemia. Leukemia. 2011;25:130\u20134.","journal-title":"Leukemia"},{"key":"1231_CR6","doi-asserted-by":"crossref","unstructured":"Bataller A, Chien KS, Sasaki K, Montalban-Bravo G, Kanagal-Shamanna R, Urrutia S, et al. PHF6 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia. Leukemia Res. 2023;127:107044.","DOI":"10.1016\/j.leukres.2023.107044"},{"key":"1231_CR7","doi-asserted-by":"crossref","unstructured":"Tefferi A, Fathima S, Alsugair AKA, Aperna F, Natu A, Abdelmagid MG, et al. PHF6 mutations in chronic myelomonocytic leukemia identify a unique subset of patients with distinct phenotype and superior prognosis. Am J Hematol. 2024;99:2321\u20137.","DOI":"10.1002\/ajh.27492"},{"key":"1231_CR8","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1038\/leu.2016.212","volume":"30","author":"T Mori","year":"2016","unstructured":"Mori T, Nagata Y, Makishima H, Sanada M, Shiozawa Y, Kon A, et al. Somatic mutations in 1760 cases with various myeloid neoplasms. Leukemia. 2016;30:2270\u20133.","journal-title":"Leukemia"},{"key":"1231_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46134-w","volume":"15","author":"Y Kubota","year":"2024","unstructured":"Kubota Y, Gu X, Terkawi L, Bodo J, Przychodzen BP, Awada H, et al. Molecular and clinical analyses of PHF6 mutant myeloid neoplasia provide their pathogenesis and therapeutic targeting. Nat Commun. 2024;15:1832.","journal-title":"Nat Commun"},{"key":"1231_CR10","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1002\/cam4.5173","volume":"12","author":"KX Huang","year":"2023","unstructured":"Huang KX, Wang L, Zheng YL, Yue CY, Xu XD, Chen HB, et al. mutation is associated with poor outcome in acute myeloid leukaemia. Cancer Med. 2023;12:2795\u2013804.","journal-title":"Cancer Med"},{"key":"1231_CR11","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"1231_CR12","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","volume":"128","author":"C Elena","year":"2016","unstructured":"Elena C, Gall\u00ec A, Such E, Meggendorfer M, Germing U, Rizzo E, et al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016;128:1408\u201317.","journal-title":"Blood"},{"key":"1231_CR13","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"1231_CR14","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sol\u00e9 F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454\u201365.","journal-title":"Blood"},{"key":"1231_CR15","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/ajh.27216","volume":"99","author":"A Tefferi","year":"2024","unstructured":"Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024;99:697\u2013718.","journal-title":"Am J Hematol"},{"key":"1231_CR16","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, et al. DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29:392\u20137.","journal-title":"J Clin Oncol"},{"key":"1231_CR17","doi-asserted-by":"crossref","unstructured":"Chien KS, Kanagal-Shamanna R, Naqvi K, Sasaki K, Alvarado Y, Takahashi K, et al. The impact of mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. Blood. 2019;134.","DOI":"10.1182\/blood-2019-131188"},{"key":"1231_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.704471","volume":"11","author":"JH Kurzer","year":"2021","unstructured":"Kurzer JH, Weinberg OK. PHF6 mutations in hematologic malignancies. Front Oncol. 2021;11:704471.","journal-title":"Front Oncol"},{"key":"1231_CR19","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1038\/s41375-023-01953-6","volume":"37","author":"SB Hou","year":"2023","unstructured":"Hou SB, Wang XM, Guo TX, Lan YJ, Yuan SN, Yang S, et al. PHF6 maintains acute myeloid leukemia via regulating NF-\u03baB signaling pathway. Leukemia. 2023;37:1626\u201337.","journal-title":"Leukemia"},{"key":"1231_CR20","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1101\/gad.254151.114","volume":"29","author":"CE Meacham","year":"2015","unstructured":"Meacham CE, Lawton LN, Soto-Feliciano YM, Pritchard JR, Joughin BA, Ehrenberger T, et al. A genome-scale in vivo loss-of-function screen identifies as a lineage-specific regulator of leukemia cell growth. Genes Dev. 2015;29:483\u20138.","journal-title":"Genes Dev"},{"key":"1231_CR21","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1038\/s41375-024-02340-5","volume":"38","author":"SS Jalnapurkar","year":"2024","unstructured":"Jalnapurkar SS, Pawar AS, George SS, Antony C, Somers P, Grana J, et al. PHF6 suppresses self-renewal of leukemic stem cells in AML. Leukemia. 2024;38:1938\u201348.","journal-title":"Leukemia"},{"key":"1231_CR22","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.apsb.2021.10.025","volume":"12","author":"HI Tsai","year":"2022","unstructured":"Tsai HI, Wu Y, Huang R, Su D, Wu Y, Liu X, et al. PHF6 functions as a tumor suppressor by recruiting methyltransferase SUV39H1 to nucleolar region and offers a novel therapeutic target for PHF6-muntant leukemia. Acta Pharm Sin B. 2022;12:1913\u201327.","journal-title":"Acta Pharm Sin B"},{"key":"1231_CR23","doi-asserted-by":"crossref","unstructured":"Patnaik MM, Tefferi A. Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia. Blood Cancer J. 2016;6:393.","DOI":"10.1038\/bcj.2016.5"},{"key":"1231_CR24","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1200\/JCO.2011.35.6394","volume":"30","author":"J Schanz","year":"2012","unstructured":"Schanz J, T\u00fcchler H, Sol\u00e9 F, Mallo M, Lu\u00f1o E, Cervera J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an International Database Merge. J Clin Oncol. 2012;30:820\u20139.","journal-title":"J Clin Oncol"},{"key":"1231_CR25","doi-asserted-by":"publisher","first-page":"11491.","DOI":"10.1182\/blood-2022-168466","volume":"140","author":"YA Chen","year":"2022","unstructured":"Chen YA, Sin CF, Tu LG, Chan HY, He FF, Wang DD, et al. Pathogenetic role of RNA splicing and NRAS mutation combination in chronic myelomonocytic leukemia. Blood. 2022;140:11491.","journal-title":"Blood"},{"key":"1231_CR26","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1182\/blood.2021012519","volume":"139","author":"XN You","year":"2022","unstructured":"You XN, Liu FB, Binder M, Vedder A, Lasho T, Wen Z, et al. Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation. Blood. 2022;139:1066\u201379.","journal-title":"Blood"},{"key":"1231_CR27","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1182\/bloodadvances.2022009010","volume":"7","author":"CA Lachowiez","year":"2023","unstructured":"Lachowiez CA, Long N, Saultz J, Gandhi A, Newell LF, Hayes-Lattin B, et al. Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia. Blood Adv. 2023;7:1899\u2013909.","journal-title":"Blood Adv"},{"key":"1231_CR28","doi-asserted-by":"crossref","unstructured":"Mishra A, Al Ali NH, Corrales-Yepez M, Padron E, Zhang L, et al. Validation of the Revised International Prognostic Scoring System (R-IPSS) for patients with myelodysplastic syndromes: therapeutic implications. Blood. 2012;120.","DOI":"10.1182\/blood.V120.21.2816.2816"},{"key":"1231_CR29","doi-asserted-by":"publisher","first-page":"4337.","DOI":"10.1182\/blood.V128.22.4337.4337","volume":"128","author":"G Todisco","year":"2016","unstructured":"Todisco G, Gall\u00ec A, Travaglino E, Rizzo E, Molteni E, Elena C, et al. SRSF2 Mutations identify a distinct subtype of myeloid neoplasm across myelodysplastic syndromes and acute myeloid leukemia. Blood. 2016;128:4337.","journal-title":"Blood"},{"key":"1231_CR30","doi-asserted-by":"crossref","unstructured":"Wu SJ, Kuo YY, Hou HA, Li LY, Tseng MH, Huang CF, et al. The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution. Blood. 2012;120:3106\u201311.","DOI":"10.1182\/blood-2012-02-412296"},{"key":"1231_CR31","doi-asserted-by":"publisher","first-page":"849376","DOI":"10.3389\/fonc.2022.849376","volume":"12","author":"M Jawad","year":"2022","unstructured":"Jawad M, Afkhami M, Ding Y, Zhang X, Li P, Young K, et al. DNMT3A R882 mutations confer unique clinicopathologic features in MDS including a high risk of AML transformation. Front Oncol. 2022;12:849376.","journal-title":"Front Oncol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01231-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01231-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01231-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T08:40:06Z","timestamp":1740818406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01231-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1231"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01231-x","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,1]]},"assertion":[{"value":"18 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SF: Nothing to disclose; AAS: Nothing to disclose; KHB: Nothing to disclose; AAM: Nothing to disclose; AP: Nothing to disclose KKR: Nothing to disclose; RH: Nothing to disclose; CZM: Nothing to disclose; NG: Advisory board to DISC Medicine and Agios; AT: Nothing to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Institutional Review Board of the Mayo Clinic (IRB protocol number: 12-003574). All methods were performed in accordance with the Declaration of Helsinki, the relevant guidelines, and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"28"}}